Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
IPO Year:
Exchange: NASDAQ
Website: https://www.sunshinebiopharma.com
FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 third quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $8,435,178 for the three months ended September 30, 2024, a 42% increase over gross revenues of $5,957,668 for same period in 2023. For the nine-month period ended September 30, 2024, gross revenues were $25,279,291, compared to gross revenue of $16,412,586 for the same period in 2023, an increase of 5
FORT LAUDERDALE, FL / ACCESSWIRE / September 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs.The first product is Varenicline, a generic version of Champix®. Varenicline is used as a smoking cessation product and is available in formats of 0.5 mg and 1 mg tablets, as well as a convenient starter kit.The second is Betahistine, a generic version of Serc®, to treat patients with vertigo. Betahistine is available in
Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18%Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both submicromolar potency and animal model efficacyXR8-23 (Compound 10) showed significant drug accumulation in lung of mice and favorable pharmacokinetic propertiesResearch was conducted in collaboration with the University of Arizona FORT LAUDERDALE, FL / ACCESSWIRE / September 4, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the
FORT LAUDERDALE, FL / ACCESSWIRE / August 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has launched nine (9) new generic prescription drugs year-to-date. These launches bring the total number of drugs that the Company has on the market in Canada to sixty-one (61). The Company's marketing and sales efforts are carried out by Nora Pharma Inc. (Nora Pharma), a wholly owned subsidiary of the Company.The new generic prescription drugs launched include Abiraterone, Clobetasol, Daptomycin, Dasatinib, Ertapenem, Hanz
FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 second quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $9,303,067 for the three months ended June 30, 2024, a 67% increase over gross revenues of $5,560,865 for same period in 2023. For the six-month period ended June 30, 2024, gross revenues were $16,844,113, compared to gross revenue of $10,454,918 for the same period in 2023, an increase of 61%. These
FORT LAUDERDALE, FL / ACCESSWIRE / August 6, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, announced today a one for twenty reverse split of its common stock, effective at market open on August 8, 2024. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing.About Sunshine Biopharma, Inc.Sunshine Biopharma currently sells 52 generic prescription drugs in Canada and has 32 additional drugs scheduled to be launched in Canada in 2024 and 2025. In
NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 first quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $7,541,046 for the quarter ended March 31, 2024, a 54% increase over gross revenues of $4,894,053 for same period in 2023. The increase is due to new product launches and expanded marketing and sales efforts by the Company's wholly owned Canadian subsidiary, Nora Pharma Inc.The following are the Company's 2024 f
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, is happy to announce that its wholly owned generic pharmaceutical subsidiary, Nora Pharma, has received approval for its first Biosimilar product.Nora Pharma has received approval from Health Canada for the commercialization of NIOPEG® (a pegylated form of filgrastim) in Canada. The current market size of pegfilgrastim in Canada is approximately $88 million USD.NIOPEG® is a Biosimilar comparable to the reference biologic drug NEULASTA® (pegfilgrastim). NIOPEG® is a long-
NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, announced today a one for one hundred reverse split of its common stock, effective at market open on April 17, 2024. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing.About Sunshine Biopharma, Inc.Sunshine Biopharma currently sells 52 generic prescription drugs in Canada and has 32 additional drugs scheduled to be launched in Canada in 2024 and 2025. In ad
Sales Grew at an Average Rate of 14% Per Quarter During the YearNEW YORK, NY / ACCESSWIRE / April 1, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 financial results on Form 10-K on Thursday March 28, 2024. The following are highlights of the report:Sales in 2023 grew to a total of $24,092,787, primarily as a result of a full year of revenues generated by the acquisition of Nora Pharma in October 2022. Nora Pharma's revenues for its fiscal year ended June 30, 2022, were $10,766,982.The average 202
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)
SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)
SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)
SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)
SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
3 - Sunshine Biopharma, Inc (0001402328) (Issuer)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
3 - Sunshine Biopharma, Inc (0001402328) (Issuer)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
3 - Sunshine Biopharma, Inc (0001402328) (Issuer)
3 - Sunshine Biopharma, Inc (0001402328) (Issuer)
424B4 - Sunshine Biopharma Inc. (0001402328) (Filer)
EFFECT - Sunshine Biopharma Inc. (0001402328) (Filer)
8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
POS AM - Sunshine Biopharma Inc. (0001402328) (Filer)
10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)
8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
DEF 14A - Sunshine Biopharma, Inc (0001402328) (Filer)
8-K - Sunshine Biopharma, Inc (0001402328) (Filer)
10-Q/A - Sunshine Biopharma, Inc (0001402328) (Filer)
8-K - Sunshine Biopharma, Inc (0001402328) (Filer)
MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. As such, Nora Pharma Inc. is now a wholly owned subsidiary of Sunshine Biopharma Inc. Nora Pharma is one of North America's fastest growing generic pharmaceuticals companies. The addition of Nora Pharma allows Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars. The purchase price of $30,000,000 Canadian (approxi
On June 28, 2024, Sunshine Biopharma, Inc. (the "Company") received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"), informing the Company that the Nasdaq Hearings Panel has granted the Company's request for an exception until August 26, 2024, to regain compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2)
Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 72.1% to $1.91 during Wednesday's regular session. The company's market cap stands at $4.8 million. Nexalin Technology (NASDAQ:NXL) shares increased by 43.06% to $1.08. The market value of their outstanding shares is at $8.0 million. Vaxart (NASDAQ:VXRT) shares rose 33.45% to $0.7. The market value of their outstanding shares is at $123.8 million. Sunshine Biopharma (NASDAQ:SBFM) stock increased by 28.92% to $0.39. The market value of their outstanding shares is at $7.4 million. Portage Biotech (NASDAQ:PRTG) shares increased by 25.0% to $0.3. The company's market cap stands at $5.9 million. Silk Road Medical (NASDAQ:SILK) shares
Gainers Nexalin Technology (NASDAQ:NXL) shares rose 55.8% to $1.62 during Tuesday's after-market session. The market value of their outstanding shares is at $12.0 million. Dynatronics (NASDAQ:DYNT) stock rose 14.74% to $0.4. The company's market cap stands at $2.1 million. Oncology Institute (NASDAQ:TOI) shares moved upwards by 10.8% to $0.45. The market value of their outstanding shares is at $33.5 million. SAB Biotherapeutics (NASDAQ:SABS) stock rose 8.94% to $2.8. The market value of their outstanding shares is at $25.8 million. Bone Biologics (NASDAQ:BBLG) shares moved upwards by 8.04% to $1.61. The company's market cap stands at $1.7 million. Virpax Pharmaceuticals (NASDAQ:VRPX) s
https://www.capitoltrades.com/trades/20003774100
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has discontinued the program. Skye Bioscience shares tumbled 18.9% to $8.87 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) shares jumped 123% to $4.3001 following the completion of the company’s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week. KWESST Micro Systems Inc. (NASDAQ:KWE) gained 79.8% to $0.7082 after the company was aw
Gainers Seres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. Renovaro (NASDAQ:RENB) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. Nanoviricides (AMEX:NNVC) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. Semler Scientific (NASDAQ:SMLR) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. TransCode Therapeutics (N
Gainers Calidi Biotherapeutics (AMEX:CLDI) shares rose 29.7% to $0.25 during Monday's pre-market session. The market value of their outstanding shares is at $16.0 million. Entero Therapeutics (NASDAQ:ENTO) shares rose 22.41% to $2.99. The company's market cap stands at $8.2 million. TransCode Therapeutics (NASDAQ:RNAZ) stock increased by 19.09% to $1.31. The company's market cap stands at $8.6 million. Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 15.3% to $0.47. The market value of their outstanding shares is at $33.2 million. CERo Therapeutics Hldgs (NASDAQ:CERO) shares moved upwards by 15.12% to $0.78. The company's market cap stands at $11.6 million. Co-Diagnostics (NASDAQ:
Shares of KKR & Co. Inc. (NYSE:KKR) rose sharply in today's pre-market trading after it was announced the company will join the S&P 500. S&P Dow Jones Indices announced late Friday changes to various S&P indices, coinciding with the quarterly rebalance. KKR will take the place of Comerica Inc. (NYSE:CMA) in the broader gauge. KKR & Co. shares jumped 10.4% to $108.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) rose 165% to $5.05 in today's pre-market trading. New Horizon Aircraft Ltd. (NASDAQ:HOVR) gained 90.1% to $1.37 in pre-market trading after declining around 8% on Frid
Gainers Anitra (AMEX:AZTR) stock rose 17.0% to $0.17 during Friday's after-market session. The company's market cap stands at $5.0 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 12.79% to $3.35. The company's market cap stands at $1.9 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares moved upwards by 9.17% to $0.45. The company's market cap stands at $2.1 million. TRACON Pharma (NASDAQ:TCON) stock rose 8.77% to $1.24. The market value of their outstanding shares is at $3.3 million. TransCode Therapeutics (NASDAQ:RNAZ) stock increased by 6.36% to $1.17. The market value of their outstanding shares is at $7.7 million. China Pharma Holdings, Inc. Common Stock (AM